2020
574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation
Schiffer M, Perreault S, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation. Open Forum Infectious Diseases 2020, 7: s352-s352. PMCID: PMC7776323, DOI: 10.1093/ofid/ofaa439.768.Peer-Reviewed Original ResearchCytokine release syndromeHaploidentical hematopoietic stem cell transplantationHematopoietic stem cell transplantationFebrile neutropeniaHaplo-HSCTStem cell transplantationRelease syndromeBreakthrough infectionsCell transplantationRecurrent feverEmpiric broad-spectrum antibiotic therapyRates of FNBroad-spectrum antibiotic therapyMulti-drug resistant organismsHaplo-HSCT patientsNon-infectious complicationsPost-transplant cyclophosphamideStem cell infusionBlood culture dataPositive blood culturesBroad-spectrum antibioticsYale New Haven HealthBackground FeverAntibacterial prophylaxisSecondary endpoints
2019
2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT)
Perreault S, McManus D, Pulk R, Topal J, Foss F, Isufi I, Seropian S, Bar N. 2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT). Open Forum Infectious Diseases 2019, 6: s947-s947. PMCID: PMC6809600, DOI: 10.1093/ofid/ofz360.2371.Peer-Reviewed Original ResearchAutologous hematopoietic stem cell transplantationHematopoietic stem cell transplantationPost-hematopoietic stem cell transplantationAutologous HSCT patientsAerosolized pentamidinePJP prophylaxisHSCT patientsPJP infectionYear post-hematopoietic stem cell transplantationYale-New Haven HospitalRisk of cytopeniaHigh-dose corticosteroidsStem cell transplantationNew Haven HospitalYears of ageCost of drugsAP prophylaxisDose corticosteroidsJiroveci infectionMonth regimenPrimary endpointRelapsed diseaseSecondary endpointsImmunomodulatory drugsRetrospective study
2015
Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders
Branagan A, Duffy E, Boddupall C, Albrecht R, Zhang L, Verma R, Cooper D, Seropian S, Parker T, Yao X, Ferencz T, Dhodapkar M. Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. Blood 2015, 126: 3058. DOI: 10.1182/blood.v126.23.3058.3058.Peer-Reviewed Original ResearchHigh-dose influenza vaccineHigh-dose vaccinePlasma cell disordersNovel vaccination strategiesProtective HAI titersCell-mediated immunityMultiple myeloma patientsNovel vaccine strategiesInfluenza vaccineVaccination strategiesSignificant unmet needInfluenza vaccinationHAI titersPCD patientsCell disordersFlu seasonSecondary endpointsSeroprotection ratesDose vaccineMyeloma patientsVaccine strategiesFlu infectionUnmet needInfection rateGrade 2 adverse events